top of page

3 Best Stocks Now to Soar from Covid

Writer's picture: Alpesh PatelAlpesh Patel

Many stocks will benefit from the rollout of the Covid 19 vaccine.

According to a Bank of America research note, “Companies in bioprocess and manufacturing may see revenues if a vaccine is produced at risk and never approved, while others, like drugstores, benefit only if people are vaccinated,” the team wrote. “Logistics companies tend to be somewhere in the middle, benefiting from some at-risk production but ultimately, the vaccine needs to be consumed and re-ordered for real benefits to accrue.”

Of the names they mention, I’ve filtered down to the ones which meet my tighter filters of cash flow growth, earnings growth, and a share price which is not high relative to profits the company makes.

Stocks of Covid 19: Danaher

Market cap: $158.97 billion

Vaccine revenue opportunity: $1.3 billion – $2.4 billion (base case); $5.3 billion – $9.9 billion (bull case)

Vaccine supply chain category: Manufacturing

Source: Bank of America

Alpesh Patel Telegram

Stocks of Covidm 19: Thermo Fisher

Market cap: $186.86 billion

Vaccine revenue opportunity: $1.3 billion – $2.4 billion (base case); $5.3 billion – $9.9 billion (bull case)

Vaccine supply chain category: Manufacturing

Source: Bank of America

Stocks of Covid 19: Merck

Market cap: $209.93 billion

Vaccine revenue opportunity: $1.3 billion – $2.4 billion (base case); $5.3 billion – $9.9 billion (bull case)

Vaccine supply chain category: Manufacturing

Source: Bank of America

Source: Bank of America, Business Insider

Alpesh Patel

36 views0 comments

Recent Posts

See All

Comments


Our website offers information about investing and saving, but not personal advice. If you're not sure which investments are right for you, please request from example from a regulated financial advisor. If you decide to invest, read our important investment notes first and remember that investments can go up and down in value, so you could get back less than you put in. Remember all trading is risky. The information provided on this website and all communications is intended for research and educational purposes only. Articles and/or screen shots featuring individual investments are not recommendations to buy or sell. Articles containing investment analysis and related comment may be out-of-date when you read them. You should do your own research into any investment before deciding to buy or sell. The aim of our products and educational resources is to help you to perform this research effectively, quickly and with confidence.It is based on our journalist comment provided elsewhere and in our books and on TV.

London Office

Alpesh Patel Ventures Limited, c/o Praefinium 84 Brook St, Mayfair, London, United Kingdom, W1K 5EH 

24/7 live: +44 34505 63799  paresh@tradermind.com

Luxembourg Office

Alpesh Patel Ventures Limited, c/o Praefinium SICAV-FIS 20, Boulevard Emmmanuel Servais, L-2535 Luxembourg

  • TikTok
  • linkedin
  • twitter
  • facebook
  • instagram
  • youtube
  • googlePlus
  • flickr

©2025 Alpesh Patel Ventures Limited.

bottom of page